ClinicalTrials.gg

Program

Utrogestan

Its studies are led by Calla Lily Clinical Care.

Furthest: phase 1, since Jul 28, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Calla Lily Clinical Care11 open or runningphase 1since Jul 28, 2025Jul 28, 2025Dec 31, 2026phase 1 · NCT07136922

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2025First study: phase 1 study in Luteal Phase InsuffiencyFirst studyNCT07136922 · 20 planned · United Kingdom

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Luteal Phase InsuffiencyNCT07136922

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
LevonorgestrelruleBayerphase 456
drospirenoneruleestetraphase 420
Megestrol AcetateruleChangchun GeneScience Pharmaceuticalphase 419
Medroxyprogesterone AcetaterulePfizerphase 411
Cyproterone AcetateruleEurofarma Laboratoriosphase 34

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07136922Luteal Phase Insuffiency · United Kingdom1RecruitingDec 31, 202620

How it is read

Names in the registry

  • “Cyclogest 400 mg”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.